- Home
- FGB vs RENB Comparison
FGB vs RENB Comparison
Compare FGB & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- RENB
- Stock Information
- Founded
- FGB 2007
- RENB 2011
- Country
- FGB United States
- RENB United States
- Employees
- FGB N/A
- RENB N/A
- Industry
- FGB Finance/Investors Services
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- FGB Finance
- RENB Health Care
- Exchange
- FGB Nasdaq
- RENB Nasdaq
- Market Cap
- FGB 60.1M
- RENB 61.0M
- IPO Year
- FGB N/A
- RENB N/A
- Fundamental
- Price
- FGB $3.88
- RENB $0.31
- Analyst Decision
- FGB
- RENB
- Analyst Count
- FGB 0
- RENB 0
- Target Price
- FGB N/A
- RENB N/A
- AVG Volume (30 Days)
- FGB 53.0K
- RENB 736.8K
- Earning Date
- FGB 01-01-0001
- RENB 05-19-2025
- Dividend Yield
- FGB 8.92%
- RENB N/A
- EPS Growth
- FGB N/A
- RENB N/A
- EPS
- FGB N/A
- RENB N/A
- Revenue
- FGB N/A
- RENB N/A
- Revenue This Year
- FGB N/A
- RENB N/A
- Revenue Next Year
- FGB N/A
- RENB N/A
- P/E Ratio
- FGB N/A
- RENB N/A
- Revenue Growth
- FGB N/A
- RENB N/A
- 52 Week Low
- FGB $2.85
- RENB $0.29
- 52 Week High
- FGB $3.74
- RENB $2.34
- Technical
- Relative Strength Index (RSI)
- FGB 47.05
- RENB 36.60
- Support Level
- FGB $3.76
- RENB $0.29
- Resistance Level
- FGB $3.87
- RENB $0.35
- Average True Range (ATR)
- FGB 0.07
- RENB 0.05
- MACD
- FGB 0.02
- RENB 0.01
- Stochastic Oscillator
- FGB 68.00
- RENB 16.20
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.